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Abstract
Background: Early intervention against cachexia necessitates a predictive model. The aims of this study were to
identify predictors of cachexia development and to create and evaluate accuracy of a predictive model based on
these predictors.
Methods: A secondary analysis of a prospective, observational, multicentre study was conducted. Patients, who
attended a palliative care programme, had incurable cancer and did not have cachexia at baseline, were amenable
to the analysis. Cachexia was defined as weight loss (WL) > 5% (6 months) or WL > 2% and body mass index< 20
kg/m2. Clinical and demographic markers were evaluated as possible predictors with Cox analysis. A classification
and regression tree analysis was used to create a model based on optimal combinations and cut-offs of significant
predictors for cachexia development, and accuracy was evaluated with a calibration plot, Harrell’s c-statistic and
receiver operating characteristic curve analysis.
Results: Six-hundred-twenty-eight patients were included in the analysis. Median age was 65 years (IQR 17),
359(57%) were female and median Karnofsky performance status was 70(IQR 10). Median follow-up was 109 days
(IQR 108), and 159 (25%) patients developed cachexia. Initial WL, cancer type, appetite and chronic obstructive
pulmonary disease were significant predictors (p ≤ 0.04). A five-level model was created with each level carrying an
increasing risk of cachexia development. For Risk-level 1-patients (WL < 3%, breast or hematologic cancer and no or
little appetite loss), median time to cachexia development was not reached, while Risk-level 5-patients (WL 3–5%)
had a median time to cachexia development of 51 days. Accuracy of cachexia predictions at 3 months was 76%.
Conclusion: Important predictors of cachexia have been identified and used to construct a predictive model of
cancer cachexia.
Trial registration: ClinicalTrials.gov Identifier: NCT01362816.
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Background
Cachexia is present in up to half of patients with cancer
[1]. It adversely affects the well-being of many patients
with cancer by inducing progressive weight loss as well as
impairing appetite, physical function and quality of life [2].
Moreover, cachexia increases mortality and impedes deliv-
ery of anti-cancer treatment [3].
To date, there is no licensed treatment and no stand-
ard of care for patients with cancer cachexia. Corticoste-
roids have been shown to improve fatigue [4] and
progestins have improved weight loss, however lack of
positive effects on lean body mass, physical function or
nutritional intake means that these agents have limited
clinical benefits [5]. Further, the side effects of these
drugs often outweigh potential benefits. Recently, select-
ive androgen receptor modulators and ghrelin agonists
have been examined in this area, however lack of dem-
onstrable effects on lean body mass and/or function
mean that these have not been granted regulatory ap-
proval for the treatment of cachexia [6, 7].
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One of the reasons that the aforementioned and other
agents may have proven inefficacious is that they may
not have been used at the optimal time point and/or in
patients truly at risk of developing cachexia. It has been
argued that to optimise efficacy of cachexia medications,
treatment should be initiated as early as possible [8];
even before cachexia is established, termed pre-cachexia.
Pre-cachexia is the first part of a cachexia staging system
based on a trajectory format with the latter two being
cachexia and refractory cachexia [9]. In this staging sys-
tem, cachexia was defined as more than 5% weight loss
in 6 months, or more than 2% weight loss if low body
mass index (< 20 kg/m2) or sarcopenia were present. Re-
fractory cachexia ensues when the cancer becomes pro-
catabolic and unresponsive to anti-cancer treatment.
Pre-cachexia was proposed as a stage where early clinical
and metabolic signs such as anorexia and inflammation
were present, but substantial weight loss was not [9]. The
intention was to separate patients likely to develop cachexia
from those who are not. However, diagnostic criteria were
not suggested, and the challenge remains to optimally strat-
ify patients into high and low risk groups. Several attempts
at defining criteria for pre-cachexia have been made. These
attempts have mostly been based on cross-sectional data or
analyses of overall survival, study designs that are inad-
equate in showing if the criteria in question imply a greater
risk of developing cachexia over time [10–12].
Therefore, the primary aim of this study was to iden-
tify which factors most strongly predict development of
cachexia in a prospective cohort of patients with incur-
able cancer. Secondary aims were to construct a model
to predict cachexia based on the optimal combinations
and cut-offs of the identified predictors, and to evaluate
the model’s accuracy.
Methods
Patients and study design
Between April 2011 and October 2013, 1739 patients
from 30 centres across Europe (27), Canada (2) and
Australia (1) were included in the European Palliative
Care Cancer Symptom study (EPCCS). The participating
centres are presented in the main publication originating
from this study [13]. EPCCS was a prospective observa-
tional study conducted by the European Palliative Care
Research Centre (PRC) (https://oslo-universitetssykehus.
no/avdelinger/kreftklinikken/avdeling-for-kreftbehand-
ling/prc) and the European Association for Palliative
Care (EAPC) Research Network (https://www.eapcnet.
eu/research/research-network). The overall aim of the
EPCCS study was to improve the understanding of symp-
tom development, and how these symptoms may best be
assessed and classified in order to improve symptom man-
agement. Eligible patients met the following key inclusion
criteria: ≥18 years of age; with incurable cancer and
attending a palliative care program. Data pertaining to
cancer cachexia were retrieved from this dataset and
assessed as part of the present study.
Data collection and assessments
Patients were assessed at baseline and then approximately
every 4 weeks for at least three follow-up visits or until
death. The following information was collected: Demo-
graphical data (age, gender, geographical region and treat-
ment setting [inpatient, outpatient, home care]), disease
specific data (cancer type and stage [localized vs. meta-
static]), height, current body weight and patient reported
weight loss in the 6months prior to inclusion. Weight loss
at subsequent visits was calculated by adding measured
weight change to baseline reported weight loss. Cachexia
was diagnosed at first occurrence of either a) weight loss >
5% since 6months prior to inclusion or b) weight loss > 2%
since 6months prior to inclusion if current body mass index
(BMI) < 20 kg/m2. All patients were assessed for cachexia at
baseline. If anyone had insufficient data to be assessed for
cachexia at baseline, data from the first follow up visit was
used as baseline registrations if available. Only patients with-
out cachexia at baseline were included in the analysis.
Performance status was assessed according to Karnofsky
Performance Status (KPS) (0–100). Comorbidities in
terms of heart disease, renal disease, chronic obstructive
pulmonary disease (COPD) or arthritis were registered.
The dataset was not sufficiently large to assess the risk
of cachexia development of each individual cancer type.
Thus, cancer type was grouped a priori into one of three
categories: Low risk - Breast cancer and haematological
cancers (lymphoma, leukemia and myelomatosis); High
risk – pancreatic and gastric cancer; Neutral risk - all
other cancers. This was based on previous literature on
cancer type and association with cachexia [14, 15].
The following patient reported outcome measurements
(PROMs) were registered: Food intake was assessed as
“less than usual”, “more than usual” or “unchanged” ac-
cording to the abridged Patient-Generated Subjective Glo-
bal Assessment (aPG-SGA) [16]. Physical and emotional
functioning (0 [worst] - 100 [best]), anorexia and fatigue
(0[best] – 100 [worst]) were assessed according to the
European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC-QLQ) C15
PAL [17]. Both instruments are widely used, and well vali-
dated in the target population.
Statistical considerations
Patients who developed cachexia during follow up were
identified and the remaining patients were censored at the
time of their last body weight registration. Time to cach-
exia development or censoring was calculated. Univariable
Cox Proportional Hazards method was used to estimate
hazard rate ratios (HR) for cachexia development with the
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following predictors assessed at baseline: Age, gender, can-
cer type (low risk, neutral risk or high risk), cancer stage,
comorbidity, weight loss, BMI, performance status, phys-
ical functioning, emotional functioning, fatigue, food in-
take and appetite. All predictors with p-value < 0.20 were
included in a multivariable Cox model. Multicollinearity
among the candidate predictors was checked by estimat-
ing Spearman’s correlation coefficients. The least signifi-
cant predictors were dropped from the multivariable
model one by one in a manual backwards selection, until
only significant predictors remained. All possible interac-
tions among the remaining predictors were examined and
added to the model if significant. Due to known associ-
ation between COPD and lung cancer [18], a sensitivity
analysis specifically adjusting for lung cancer alongside the
a priori cancer type categorization (low risk, neutral risk,
high risk) was performed.
In order to construct a model that uses optimal com-
binations and cut--offs of the identified risk factors to
predict cachexia development, a classification and re-
gression tree (CART) analysis for failure time data was
used. CART is a non-parametric data-mining procedure
which examines all possible cut-offs of every variable to
create separate subgroups of significantly different risks.
It repeatedly splits the population based on the variable
and cut-off that most optimally stratifies risk of cachexia
development in the current group. It stops when signifi-
cant divisions no longer can be performed. The final
subgroups were compared, and adjacent subgroups with
similar risk of cachexia development were merged to
create levels of increasing risk of cachexia development.
Kaplan-Meier curves were plotted for each risk-level,
and both log-rank test for differences in cachexia devel-
opment probabilities among risk levels, and test for
trend in cachexia development probabilities (i.e. cachexia
development probability of Risk-level 1 ≤ Risk-level 2 ≤
… ≤ Risk-level 5) were performed. To assess accuracy of
this model, a calibration plot was created by plotting pre-
dicted vs. observed risk at 3 months, and Harrell’s c-
statistic was estimated to assess discriminatory capacity.
In addition, receiver operating characteristic (ROC) curve
analysis at 3 months in patients alive and still on study
was performed. For the different possible cut-offs of a
diagnostic test (all possible cut-offs for the “prediction
function” from the model in this case), the ROC curve is a
plot of the true positive rate (sensitivity, i.e. the proportion
of patients correctly classified by the model among those
actually developing cachexia) against the false positive rate
(1- specificity, i.e. the proportion of patients wrongly clas-
sified as “developing cachexia” by the model, among those
actually not developing cachexia). This was done to evalu-
ate if a cut-off with both high sensitivity and high specifi-
city for the prediction of cachexia development could be
identified. A two-sided p-value of < 0.05 was considered
significant in all analyses, unless stated otherwise. Stata
version 13.1 (College Station, Texas, USA) was used for
statistical analyses, and the Stata-module Cart [19] was used
for the CART-analysis.
Results
A flow chart of patient selection is shown in Fig. 1. Of the
1739 patients included in the EPCCS-study, 425 patients
(24%) were excluded because of missing data necessary to
classify patients as cachexic or not cachexic. Six-hundred-
and-eighty-six patients (39%) already had cachexia at base-
line and therefore were inadmissible to further analysis,
leaving 628 (36%) patients to the final analysis.
Patient characteristics are shown in Table 1. The median
age was 65 years (IQR 17), 359 (57%) were female and me-
dian KPS was 70 (IQR 10). One-hundred-and-fifty-nine
patients (25%) developed cachexia during follow-up. For
affected individuals, cachexia occurred in a median time
of 63 days (IQR 79). Overall, minimum follow-up was 16
days and median follow-up was 109 days (IQR 108).
Table 2 shows a univariable analysis of potential predic-
tors of cachexia development. Gender, weight loss, per-
formance status, food intake, appetite loss, cancer type and
COPD were all significant predictors (p ≤ 0.02). In addition,
physical functioning and cancer stage were included in the
multivariable analysis due to p-values < 0.20. Physical func-
tioning and KPS (0.53, p < 0.001) and appetite and food in-
take (0.54, p < 0.001) had correlation coefficients > 0.5.
Fig. 1 Flow chart
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Table 1 Baseline patient characteristics
Patient characteristics (n = 628)
Median Age at inclusion (IQR) 65 (17)
Gender f (%)
Female 359 (57)
Male 269 (43)
Geographical region f (%)
Europe 578 (92)
Canada 43 (7)
Australia 7 (1)
Cancer type f (%)
Low risk cancer 184 (29)
Breast 171 (27)
Haematological 13 (2)
Neutral risk cancer 410 (65)
Lung 125 (20)
Colorectal 70 (11)
Prostate 48 (8)
Female genitalia 36 (6)
Head and neck 24 (5)
Urinary 20 (3)
Hepatobiliary 17 (3)
Sarcoma, connective and soft tissue 17 (3)
Small intestine 11 (2)
Oesophageal 8 (1)
Other 34 (5)
High risk cancer 33 (5)
Pancreatic 24 (4)
Gastric 9 (1)
Cancer stage f (%)
Local 83 (13)
Metastatic/disseminated 543 (87)
Treatment setting
Inpatients 56 (9)
Outpatients 483 (78)
Home care 77 (13)
Anti-cancer treatment
Chemotherapy 337 (54)
Hormonal therapy 81 (13)
Radiotherapy 35 (6)
Other 47 (7)
No treatment 173 (28)
Median Karnofsky PS (IQR) 70 (10)
Weight loss (6 months) f (%)
< 1% 535 (85)
1–5% 93 (15)
Table 1 Baseline patient characteristics (Continued)
Patient characteristics (n = 628)
Mean BMI (SD) 25.5 (4.5)
Comorbidities f (%)
Heart disease 165 (26)
COPD 62 (10)
Arthritis 51 (8)
Renal disease 17 (3)
Abbreviations: IQR interquartile range, PS performance status, SD standard
deviation, COPD chronic obstructive pulmonary disease
Table 2 Univariable analysis
Univariable analysis
HR 95% CI p
Age at inclusion 1.01 1.00–1.03 0.06
Gender
Male 1.5 1.1–2.0 0.01
Female 1
Weight loss (6 months) 1.6 1.4–1.7 < 0.001
BMI 0.99 0.95–1.03 0.53
Karnofsky PS (0–100) 0.98 0.97–1.00 < 0.01
Fatigue (0–100) 1.00 1.00–1.01 0.26
Physical functioning (0–100) 0.99 0.99–1.00 0.09
Emotional functioning (0–100) 1.00 0.99–1.01 0.67
Food intake
Less than usual 1.7 1.2–2.4 < 0.01
More than usual 1.0 0.6–1.7 0.93
Unchanged 1
Appetite loss (0–100) 1.01 1.01–1.02 < 0.001
Cancer stage
Metastatic/disseminated 1.7 1.0–2.9 0.07
Local 1
Cancer typea
High risk cancer 4.4 2.4–8.1 < 0.001
Neutral risk cancer 2.1 1.4–3.1 < 0.001
Low risk cancer 1
Heart disease 0.9 0.6–1.3 0.55
Renal disease 1.4 0.6–3.1 0.45
Arthritis 1.4 0.8–2.3 0.22
COPD 1.7 1.1–2.7 0.02
Abbreviations: HR hazard ratio, CI confidence interval, BMI body mass index, PS
performance status, COPD chronic obstructive pulmonary disease
aLow risk - Breast cancer, lymphoma, leukaemia; High risk – pancreatic and
gastric cancer; Neutral risk - all other cancers
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After manual backward selection, where insignificant pre-
dictors were removed one by one, weight loss, cancer type,
appetite and COPD all remained significant (p ≤ 0.04) and
were kept in the model (Table 3). A significant interaction
(p < 0.01) was demonstrated between weight loss and can-
cer type, signifying that the effect of cancer type on risk of
developing cachexia became less important if weight loss
already was high. Thirty percent of patients with lung can-
cer had COPD in contrast to the overall COPD prevalence
of 10%. Thus, a sensitivity analysis was performed adjust-
ing for lung cancer alongside the a priori cancer type clas-
sification. This analysis showed that patients with lung
cancer had a slightly higher risk of cachexia development
compared to patients classified as having neutral risk can-
cer (HR [95%CI] 2.7 [1.4–5.2] vs 2.5 [1.4–4.3], respect-
ively) and risk attributable to COPD fell slightly and
COPD no longer significantly predicted cachexia develop-
ment (HR 1.5 [0.9–2.6]).
Figure 2 shows the CART-analysis. Weight loss, cancer
type and appetite loss could be used to identify six groups
of patients, each with a homogenous risk of cachexia devel-
opment within the group. Two groups from adjacent
branches of the classification and regression tree were com-
bined due to similar hazard ratios, resulting in a model of
five levels of increasing risk of cachexia development:
1. < 3% weight loss, low risk cancer type and no/little
appetite loss
2. < 3% weight loss and either low risk cancer type
and quite a bit/very much appetite loss OR neutral
risk cancer type and no/little appetite loss
3. < 3% weight loss, neutral risk cancer type and quite
a bit/very much appetite loss
4. High risk cancer type
5. 3–5% weight loss
Figure 3 shows the Kaplan-Meier curves for time to
cachexia development in these five risk-levels. Median
time to cachexia development was not reached in Risk-
level 1, 249 days for Risk-level 2, 175 days for Risk-level 3,
145 days for Risk-level 4 and 51 days for Risk-level 5. Log-
rank test for differences in cachexia development probabil-
ities and test for trend in cachexia development probabil-
ities were both significant (p < 0.0001), confirming that
probability of cachexia development not only differed be-
tween levels, but was increasing with increasing risk-level.
The calibration plot shown in Fig. 4 demonstrates that the
risk-level model accurately predicts the observed risk of
cachexia development at 3 months, however a Harrell’s C-
statistic of 0.71 indicates only modest ability to discriminate
between patients who will and will not develop cachexia.
Figure 5 presents sensitivity and specificity of cachexia pre-
dictions at 3 months for all possible cut-offs between risk-
levels in the subsample of patients still alive and remaining
in the study after 3 months (n = 372). A risk-level ≥ 2 yielded
a sensitivity of 95% and a specificity of 35% of predicting
cachexia development, while a risk-level ≥ 3 yielded a sensi-
tivity of 47% and a specificity of 88%. Hence, there was no
single cut-off with both a high sensitivity and high specificity
of predicting cachexia. Area under the curve was 0.76, signi-
fying an accuracy in ability to discriminate between patients
with and without cachexia of 76% at 3 months, and is com-
parable to the corresponding Harrell’s c-statistic.
Discussion
This study shows that initial weight loss, cancer type, appe-
tite loss and COPD are significant and independent predic-
tors of cachexia in patients with incurable cancer. Based on
this, we identify five levels of risk of cachexia development.
The cachexia definition is based mainly on weight loss,
and thus, initial minor weight loss below the assigned cri-
teria [9] have been considered indicative of pre-cachexia
in several studies [10–12]. The present study confirms
that there is an increased risk of further weight loss and
eventual development of cachexia when minor weight loss
is present. However, the present study also identifies sev-
eral other risk factors that predict cachexia, independently
of weight loss. Among these is cancer type, which has
been associated with, and assumed to predict cachexia
[14]. The findings of the present study confirm this and
demonstrate that a classification of cancer type into low
risk cancer (breast cancer and hematologic cancers), high
risk cancer (pancreatic and gastric tumours) and neutral
risk cancer (all other cancers) significantly predicts cach-
exia development. However, findings from the CART ana-
lysis show that when weight loss is 3% or more, cancer
type does not add further to the risk of cachexia develop-
ment. Contrary to cancer type, cancer stage (localized vs.
metastatic) was not shown to predict cachexia significantly,
although a trend was noted in the univariable analysis. The
Table 3 Multivariable analysis
Multivariable analysis
HR 95% CI p
Weight loss 1.9 1.5–2.2 < 0.001
Cancer typea
Low risk 1
Neutral risk 2.5 1.5–4.3 < 0.01
High risk 6.3 2.9–13.8 < 0.001
Appetite loss (0–100) 1.005 1.000–1.011 0.04
COPD 1.6 1.0–2.6 0.04
Interactions with weight loss
Medium risk cancer 0.8 0.7–1.0 0.06
High risk cancer 0.6 0.4–0.9 < 0.01
Abbreviations: HR hazard ratio, CI confidence interval, COPD chronic
obstructive pulmonary disease
aLow risk - Breast cancer, lymphoma, leukaemia; High risk – pancreatic and
gastric cancer; Neutral risk - all other cancers
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study is not suitable to draw conclusions about cancer
stage, however, since the majority of the study population
(87%) had metastatic cancer.
Appetite loss is central in the cachexia pathophysi-
ology. It is believed that mediators of cachexia affect the
hypothalamus in such a way that the central drive to eat
weakens [20]. In turn, this might contribute to an
N HR (95%CI)
Weight loss 
Not at all/A little 146 0.4 (0.2-0.6)
Low risk
Appetite loss 
Quite a bit/Very much
23 1.0 (0.4-2.6)
0-3%
Cancer type
320 1.0
Neutral risk
52 2.0 (1.2-3.4)
Neut-High risk
Cancer type
High risk
27 2.8 (1.6-5.1)
3-5%
54 4.9 (3.3-7.3)
1
2
3
4
Risk Level 
Appetite loss 
Not at all/A little
Quite a bit/Very much
5
Fig. 2 Classification and regression tree (CART) analysis. The study population is divided repeatedly according to optimal cut-offs of the variables
weight loss (rounded to the nearest integer), cancer type and appetite loss into subdivisions of significantly different hazard rates. Adjacent
subdivisions from different branches with similar hazard rates are combined resulting in five risk-levels. Hazard ratios (HR) are reported relative to
the branch with neutral risk cancer type and no or little appetite loss
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Fig. 3 Kaplan-Meier plot of time to cachexia development
depending on risk-level. Median time to cachexia development was
not reached in level 1, 249 days for level 2, 175 days for level 3, 145
days for level 4 and 51 days for level 5. Log-rank test and test for
trend in failure time-analysis were both significant (p < 0.0001)
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Fig. 4 Calibration plot showing the risk of cachexia development
after 3 months, as predicted by the risk-level model, plotted against
the observed risk
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accelerated weight loss through lowered dietary intake.
However, conscious control of eating may sometimes
prevail over appetite loss [21], and the present study
therefore examines both appetite loss and food intake as
possible predictors of cachexia. Appetite loss is shown to
predict cachexia development independently and ap-
pears to be especially important in predicting cachexia
in patients with little weight loss (< 3%) and low or neu-
tral risk cancer. Food intake did not independently pre-
dict cachexia development, however, and reasons for this
might be collinearity (correlation coefficient 0.53) with
appetite loss and/or inadequate estimation of food
intake.
Patients with COPD had an increased risk of develop-
ing cachexia. And although a sensitivity analysis showed
that this was partly due to collinearity with lung cancer
(which was not explicitly adjusted for in the main ana-
lysis), there was still a clear trend towards increased risk
of cachexia development. This might be because COPD,
as many other chronic diseases, sometimes leads to
cachexia. A conservative estimate of the prevalence of
cachexia in COPD is 5% [22]. COPD might therefore
impose an extra risk of cachexia development on pa-
tients with cancer. However, in the subsequent CART-
analysis, COPD did not significantly discriminate be-
tween groups of patients in terms of cachexia risk, indi-
cating that its role as a risk factor is inferior to the other
three significant factors. Notably, heart disease, renal
disease and arthritis did not predict cachexia
development, although also these conditions are associ-
ated with cachexia [22].
Measurements of physical performance applied in the
present study (the Karnofsky scale and the physical
function scale of the EORTC QLQ C15 PAL) did not
predict cachexia development, independently. Analysis
of collinearity showed a moderate correlation between
Karnofsky and physical function (correlation coefficient
0.54), and collinearity can sometimes explain why two
variables that otherwise would be significant, both end
up non-significant when present together in a multivar-
iable model. However, this did most likely not explain
the lack of significant contribution to the model in the
present study as the backward selection in the multivar-
iable analysis ensured that the least significant of the
two predictors were rejected from the model before the
other. Impaired physical performance is partly caused
by the progressive loss of muscle mass that accompan-
ies cachexia [23], and is considered a late symptom [9].
This might be a more likely explanation of why markers
of physical performance did not predict cachexia.
Implications for clinical practice and future research
The present study demonstrates that information on can-
cer type, appetite loss and COPD improves accuracy of
cachexia prediction when added to the established cach-
exia classifier, weight loss. This is especially true in pa-
tients with no or minimal weight loss (< 3%), whereas in
patients with weight loss between 3 and 5%, development
of cachexia is imminent, regardless of other factors. Based
on these predictors, patients can be stratified into five dif-
ferent risk-levels of cachexia development. Cachexia de-
velopment is not likely if in Risk-level 1, and conversely,
for patients in Risk-level 3 or greater the risk of cachexia
development is high. As such, the risk-levels enable the
clinician to select which patients must be followed more
closely with respect to cachexia development and ensure
early adequate therapeutic intervention. To the researcher,
this could improve patient selection in intervention trials
aiming at preventing cachexia, by including only patients
at risk of developing cachexia.
No single cut-off in this five-level risk ladder has both
high sensitivity and high specificity of predicting cach-
exia. Thus, no single criterion was identified that accur-
ately diagnosed pre-cachexia. Future research should
attempt to improve prediction of cachexia development,
and thereby improve the diagnosis of pre-cachexia. A
likely path towards this aim is to examine the role of in-
flammatory markers in predicting cancer cachexia. In-
flammation is a central part of cachexia pathophysiology
and considered a driver of cachexia development [2],
and it is likely that markers of systemic inflammation
would improve accuracy of cancer cachexia prediction.
Thus, the addition of inflammatory markers to the
Risk level ≥ 2
Risk level ≥ 3
Risk level ≥ 4
Risk level ≥ 5
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Fig. 5 Sensitivity and specificity of cachexia prediction at 3 months
when using different cut-offs of risk-level to divide patients into a
high or low risk group of cachexia development. Risk-level ≥ 2
yields a high sensitivity (95%), while risk-level ≥ 3 yields a high
specificity (88%). No single cut-off yields both a high sensitivity
and high specificity
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predictors identified in the present study is a necessary
next step towards diagnosing pre-cachexia.
Appraisal of study design
The strength of this study is that it examines factors re-
lated to cachexia development in a large longitudinal co-
hort of patients, and thus enables the identification of
factors that predict cachexia development and their rela-
tive importance. As is common in many studies in pallia-
tive care, the number of missing follow-up observations
was relatively high. It is likely that a worsening in physical
condition is among the reasons for patients dropping out,
and this would decrease statistical power and may intro-
duce a bias. To mitigate this effect, Cox proportional haz-
ards method was used to let each patient contribute with
his or her time on the study. Furthermore, to increase
power of statistical analysis, patients with insufficient data
at baseline, but with sufficient data at first follow-up visit
were included with the latest visit as baseline. This was
considered appropriate due to the open study design,
which allowed inclusion of patients at any time point in
their disease trajectory. The CART method is a data min-
ing procedure that is simple to understand and gives an
intuitive result. As the calibration plot (Fig. 4) shows, the
resulting risk-level model fit the observed risk very well.
This is expected when evaluating the model on data from
which the model was developed, and the CART method-
ology may be criticised for creating models that are over-
fitted to the data, and thus reduce the external validity. By
only including significant factors from the Cox model, the
risk of overfitting is reduced, and, in addition, the resulting
CART model seems clinically plausible. No objective mea-
surements of body composition were available when
assessing cachexia. Effect on weight change by accumula-
tion of third space fluids or shifts between fat and muscle
mass could therefore not be assessed. However, the
adapted definition used in this study has previously been
validated [10], and it could be argued that this definition is
of greater clinical practical value as objective measures of
body composition not always are available in the clinical
setting. As mentioned above, no markers of systemic in-
flammation were assessed as possible predictors of cach-
exia development. Although the EPCCS study allowed for
registration of incidental C-reactive protein measurements
performed within 3 days before inclusion, too few obser-
vations were available to enable statistical inferences.
Conclusion
The present study identifies important risk factors for de-
velopment of cachexia and suggests how these should be
combined to optimally stratify patients in terms of cach-
exia risk. Future research should validate these results and
evaluate if addition of markers of systemic inflammation
can improve accuracy.
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